FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced non-small cell lung cancer whose disease has progressed after other treatments and with tumors that express the protein PD-L1.
City of Hope and Sorrento Therapeutics Inc. formed a company, LA Cell Inc., to focus on the development of cell-penetrating antibody therapies. LA Cell has exclusively licensed technology developed at City of Hope that enables modified monoclonal antibodies to penetrate into cells and target disease-causing molecules.
UbiVac formed a collaboration with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop new preclinical and clinical versions of UbiVac's proprietary DRibble immunotherapy for use in preclinical studies of oral cancer.
Aspen Park Pharmaceuticals Inc. acquired worldwide rights to APP-111, first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer, from The Ohio State University, through the Ohio State Innovation Foundation.
FDA approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting.
FDA approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting.
Amgen Inc. and Xencor Inc. entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
CTI BioPharma Corp. said it plans to submit a new drug application to FDA following a productive pre-NDA meeting for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.
Roche NimbleGen introduced an enhanced whole exome sequencing solution for medical and translational research.
ICON, a provider of drug development solutions, said it's working with IBM to help reduce the time and costs of drug development while also offering patients enhanced quality of care by connecting them to relevant clinical trials. ICON said it will tap Watson's cognitive computing power to help the process of identifying patients who meet the criteria for a clinical trial, and to analyze protocols to assess trial feasibility and identify optimal trial sites.
